Is the price fair?
What SYK's price assumes
Stryker Corporation trades at 34.2× earnings against 33.4× for the median Medical Devices name, more expensive than its own group.
34.2
Trailing P/E · Medical Devices median 33.4 · 1.02× the median: the market pays up for this one
- Price / sales
- 5.03
Price / sales · as of 2026-Q1
- Free cash flow yield
- 4.0%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +8.6%
Growth the price implies · The price pays for +8.6% free cash flow growth a year for a decade; the business has delivered +25% a year over the last three.
Details›
- EV / EBIT2026-Q1
- 27.7
- EV / sales2026-Q1
- 5.47
- Healthcare median P/E362 names
- 31.5
- Medical Devices median P/E39 names
- 33.4
- Free cash flow, trailing twelve months
- $4.70B
- Market capitalisation
- $118.0B
- 3-year revenue growth
- +9.9%
- 3-year free cash flow growth
- +25%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $341.94 |
| Its own P/E history, median | $387.08 |
| Its own P/E history, upper quartile | $447.10 |
| 52-week range | $282.58 – $391.41 |
| Today | $329.65 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Devices
Ranks #17 of 35 by Smart Score